Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by MEI Pharma, Inc. on November 30, 2017. The filing covers the fiscal year ending June 30, 2018. Note: The request metadata lists "Lite Strategy, Inc.", but the filing text explicitly identifies the registrant as MEI Pharma, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
Stockholders representing 27,099,630 shares (out of 36,950,177 outstanding) voted on four proposals:
- Proposal 1 (Election of Directors): Kevan E. Clemens, Ph.D., and Daniel P. Gold, Ph.D., were elected to three-year terms expiring in 2021. Significant broker non-votes (15,777,322) were recorded for this proposal.
- Proposal 2 (Ratification of Auditors): The appointment of BDO USA, LLP as the independent registered public accounting firm was approved.
- Proposal 3 (Say-on-Pay): The advisory vote on executive compensation was approved.
- Proposal 4 (Frequency of Say-on-Pay): Stockholders approved conducting the advisory vote on executive compensation annually.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on operations, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the identity of the registrant (MEI Pharma, Inc.) versus the metadata provided (Lite Strategy, Inc.).
- Review the definitive proxy statement for detailed biographical information on the newly elected directors.
- Confirm the engagement letter and scope of work with the newly ratified auditor, BDO USA, LLP.
- Check subsequent filings for the Company's financial performance for the fiscal year ending June 30, 2018, as this 8-K contains no financial data.